Retransplantation for recurrent hepatitis C in the MELD era: Maximizing Utility

Liver Transplantation

Volumn 10, Issue 10 SUPPL. 2, 2004, Pages

  Burton Jr , James R ^a,b   Sonnenberg, Amnon ^a,b   Rosen, Hugo R ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; DISEASE MODEL; DISEASE SEVERITY; GRAFT FAILURE; GRAFT SURVIVAL; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; MEDICAL ETHICS; MORTALITY; ORGAN DONOR; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; RECURRENT DISEASE; REOPERATION; RESOURCE ALLOCATION; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME;

DECISION SUPPORT TECHNIQUES; HEALTH CARE RATIONING; HEPATITIS C; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MODELS, STATISTICAL; PROGNOSIS; RECURRENCE; REOPERATION; SEVERITY OF ILLNESS INDEX;

EID: 6444224865     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20259     Document Type: Article

References (29)

1. Ganes E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9:S28-S34.
2. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-205.
3. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
4. Berenguer M, Preito M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000; 32:852-858.
5. Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-190.
6. Narayanan Menon KV, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, Rosen CB, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002;8:623-629.
7. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998;66:1612-1616.
8. Watt KDS, Lyden ER, McCashland TM. Poor survival after liver transplantation: is hepatitis C to blame? Liver Transpl 2003;9: 1019-1024.
9. Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl 2003;9:897-904.
10. Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002;8:313-222.
11. Doyle HR, Morelli F, McMichael J, Doria C, Aldrighetti L, Starzl TE, et al. Hepatic Retransplantation - an analysis of risk factors associated with outcome. Transplantation 1996;61: 1499-1505.
12. Wong T, Devlin J, Rolando N, Heaton N, Williams R. Clinical characteristic affecting the outcome of liver retransplantation. Transplantation 1997;64:878-882.
13. Markmann JF, Markowitz JS, Yersiz H, Morrisey M, Farmer DG, Farmer DA, et al. Long-term survival after retransplantation of the liver. Ann Surg 1997;226:408-418.
14. Markmann JF, Gornbein J, Markowitz JS, Levy MF, Klintmalm GB, Yersiz H, et al. A simple model to estimate survival after retransplantation of the liver. Transplantation 1999;67:422-430.
15. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999;29: 365-370.
16. Kim WR, Wiesner RH, Poterucha JJ, Therneau TM, Malinchoc M, Benson JT, et al. Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization. Hepatology 1999;30:395-400.
17. Facciuto M, Heidt D, Guarrera J, Bodian CA, Miller CM, Emre S, et al. Retransplantation for late liver graft failure: predictors of mortality. Liver Transpl 2000;6:174-179.
18. Azoulay D, Linhares MM, Huguet E, Delvart V, Castaing D, Adam R, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002;236:713-721.
19. Rosen HR, Prieto M, Casanovas-Taltavull T, Cuervas-Mons V, Guckelberger O, Muiesan P, et al. Validation and refinement of a survival models for liver retransplantation. Hepatology 2003; 38:460-469
20. Roayaie S, Schiano TD, Thung SN, Emre SH, Fishbein TM, Miller CM, et al. Results of retransplantation for recurrent hepatitis C. Hepatology 2003;38:1428-1436.
21. Ghobrial RM, Saab S, Lassman C, Lu DS, Raman S, Limanond P, et al. Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver Transpl 2002;8:901-909.
22. Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004;39:230-238.
23. Burton JR Jr, Rosen HR. Liver retransplantation for HCV recurrence: a national survey of practice patterns in liver transplant programs. Gastroenterology 2004;126(Suppl):211A.
24. Organ Procurement and Transplantation Network. Health Resources and Services Administration, HHS. Final rule. Fed Regist 1999;64:56650-56661.
25. Varian HR. Microeconomic analysis, 3rd ed. New York: WW Norton & Company, 1992:94-115.
26. Chiang AC. Fundamental methods of mathematical economics, 3rd ed. New York: McGraw-Hill Publishing Company, 1984: 400-410.
27. Onaca NN, Levy MF, Sanchez EQ, Chinnokotla S, Fasola CG, Thomas MJ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003;9:117-123.
28. Saab S, Wang V, Ibrahim AB, Durazo F, Han S, Farmer DG, et al. MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl 2003;9:473-476.
29. Kamath PS, Wiesner RH, Malinchoc M, Dremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.